GGrantIndex
← Leaderboards

Jody D. Ciolino

Northwestern University At Chicago

$7,003,382
Attributed
$14,365,384
Total exposure
4
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY201825
$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,365,384 · 4

By mechanism

U24$8,744,314 · 1
R33$3,316,760 · 1
R61$1,228,452 · 1
R01$1,075,858 · 1

Top collaborators

Most similar at Northwestern University At Chicago

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Research Personnel

Research focus

Research PersonnelSiteSafetyUnited StatesUniversitiesResourcesPreventMemberEventBiometryLeadReportingPublic HealthTrainingTreatment StrategyPharmaceutical PreparationsHybridsHuman ResourcesProspectiveClinical TrialsAmericanChicagoProtocols DocumentationFoundations

Grant awards (11)

A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy for Back Pain$497,367
R01 · FY2025 · AT
Liver Cirrhosis Network: Scientific and Data Coordination Center$2,192,940
U24 · FY2024 · DK · contact PI
A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy for Back Pain$578,491
R01 · FY2024 · AT
Liver Cirrhosis Network: Scientific and Data Coordination Center$2,064,403
U24 · FY2023 · DK · contact PI
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low dose treatment for hypertension (QUARTET USA)$544,107
R33 · FY2023 · HL
Liver Cirrhosis Network: Scientific and Data Coordination Center$2,096,971
U24 · FY2022 · DK · contact PI
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low dose treatment for hypertension (QUARTET USA)$629,010
R33 · FY2022 · HL
Liver Cirrhosis Network: Scientific and Data Coordination Center$2,390,000
U24 · FY2021 · DK · contact PI
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)$1,104,047
R33 · FY2021 · HL
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)$1,039,596
R33 · FY2019 · HL
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)$1,228,452
R61 · FY2018 · HL